Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-03-02 @ 10:04 PM
Study NCT ID:
NCT00546793
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2007-10-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Sponsor:
Gilead Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NHL | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | Lymphoma, B-Cell | View |
| None | Lymphoma, Follicular | View |
| None | Lymphoma, Intermediate-Grade | View |
| None | Lymphoma, Large-Cell | View |
| None | Lymphoma, Low-Grade | View |
| None | Lymphoma, Mixed-Cell | View |
| None | Lymphoma, Small-Cell | View |
| None | Leukemia, Lymphocytic, Chronic | View |
| None | Leukemia, B-Cell, Chronic | View |
| None | Leukemia, Prolymphocytic | View |
| None | Leukemia, Small Lymphocytic | View |
| None | Lymphoma, Small Lymphocytic | View |
| None | Lymphoma, Lymphoplasmacytoid, CLL | View |
| None | Lymphoplasmacytoid Lymphoma, CLL | View |
| None | CLL | View |
| None | SLL | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | humanized anti-CD20 veltuzumab (IMMU-106) administered subcutaneously | View |